EGFR Antibody (h-R3 (Nimotuzumab)) - Azide and BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-75186

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Human

Applications

Block/Neutralize, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry

Label

Unconjugated

Antibody Source

Monoclonal Human IgG1 kappa Clone # h-R3 (Nimotuzumab)

Format

Azide and BSA Free

Concentration

1 mg/ml

View all EGFR Antibodies »

Product Specifications

Immunogen

This antibody was generated by humanisation of the murine antibody R3, raised against EGFR purified from placenta membranes and A431 tumors.

Specificity

Binds to human EGFR domain III at a site distinct from antibody 7A7. (Talavera et al. 2011)

Clonality

Monoclonal

Host

Human

Isotype

IgG1 kappa

Scientific Data Images for EGFR Antibody (h-R3 (Nimotuzumab)) - Azide and BSA Free

Immunofluorescence: EGFR Antibody (h-R3 (Nimotuzumab)) - Azide and BSA Free [NBP2-75186]

Immunofluorescence: EGFR Antibody (h-R3 (Nimotuzumab)) - Azide and BSA Free [NBP2-75186]

Immunofluorescence: EGFR Antibody (h-R3 (Nimotuzumab)) [NBP2-75186] - Staining of fixed HeLa cells with anti-EGFR antibody h-R3 (Nimotuzumab).

Applications for EGFR Antibody (h-R3 (Nimotuzumab)) - Azide and BSA Free

Application
Recommended Usage

Flow Cytometry

1:10 - 1:1000

Immunohistochemistry

1:10 - 1:500

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

PBS

Format

Azide and BSA Free

Preservative

0.02% Proclin 300

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C for up to 3 months. For longer storage, aliquot and store at -20C.

Background: EGFR

Epidermal growth factor receptor (EGFR), also known as ErbB1 and HER1, is a type I glycoprotein that belongs the ErbB subfamily of receptor tyrosine kinases (RTKs), which includes ErbB2/HER2, ErbB3/HER3, and ErbB4/HER4 (1,2). EGFR plays an important role in epithelial cell development and homeostasis and as a driver of tumorigenesis in cancer (1,2). The human EGFR is protein 1210 amino acids (aa) in length with a theoretical molecular weight (MW) of 134 kDa (1). The protein consists of a short signal peptide, an extracellular domain (ECD) divided into four subdomains (I-IV), a transmembrane region, an intracellular juxtamembrane segment, a tyrosine kinase domain, and C-terminal tail (1-3). Within the ECD, human EGFR has 88-90% aa sequence identity with mouse and rat EGFR. EGFR has four known specific ligands: EGF, amphiregulin, epigen, and transforming growth factor alpha (TGF-alpha). EGFR ligands betacellulin, epiregulin, and herapin binding (HB)-EGF have dual specificity with ErbB4 (1,3). Ligand binding to the extracellular domain of EFGR leads to receptor homodimerization, or heterodimerization with other ErbB family members, and EGFR activation. This results in subsequent phosphorylation and activation of intracellular signaling pathways, such as MAPK and PI3K/Akt (2,3). EGFR signaling is essential for many cellular processes including proliferation, differentiation, migration, and apoptosis (1,3,5).

In addition to its role in normal development, EGFR mutations or overexpression is observed in many tumors, including breast cancer, non-small cell lung carcinoma (NSCLC), colon cancer, and more (3-6). Small molecule tyrosine kinase inhibitors (TKIs), like gefitinib, erlotinib, and afatinib, have shown great efficacy in treating patients with EGFR activating mutations, especially for NSCLC (4-6). However, most patients eventually develop acquired resistance to TKIs and thus combination and alternative therapies are in development (4-6). A third-generation TKI, osimertinib, is approved for NSCLC patients with resistance to first-line EGFR TKI treatment (6). Additionally, combination therapies of EGFR TKIs with monoclonal antibody immunotherapies, like anti-PD-L1, are being further investigated in clinical trials (6).

References

1. Roskoski R Jr. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res. 2019; 139:395-411. https://doi.org/10.1016/j.phrs.2018.11.014

2. Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018; 12(1):3-20. https://doi.org/10.1002/1878-0261.12155

3. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006; 366(1):2-16. https://doi.org/10.1016/j.gene.2005.10.018

4. Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 2018; 17(1):53. https://doi.org/10.1186/s12943-018-0793-1

5. Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020; 61:167-179. https://doi.org/10.1016/j.semcancer.2019.09.015

6. Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018; 17(1):38. https://doi.org/10.1186/s12943-018-0777-1

Long Name

Epidermal Growth Factor Receptor

Alternate Names

EGF R, ErbB, ErbB1, HER-1, biosimilar antibody, biosimilars, EGFR variant III

Gene Symbol

EGFR

Additional EGFR Products

Product Documents for EGFR Antibody (h-R3 (Nimotuzumab)) - Azide and BSA Free

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for EGFR Antibody (h-R3 (Nimotuzumab)) - Azide and BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.